NCT02877199View on ClinicalTrials.gov

Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy

CompletedOBSERVATIONAL
Enrollment

19

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Hepatitis C
Interventions
OTHER

Triple therapy

Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice

Trial Locations (1)

Unknown

Hôpital de la Croix Rousse, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02877199 - Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy | Biotech Hunter | Biotech Hunter